Please check your internet connection and try again.
# Meftal Spas
## Overview
Meftal Spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and dicyclomine hydrochloride, an anticholinergic antispasmodic.
## Primary Indications
* Management of mild to moderate pain associated with smooth muscle spasms, such as in dysmenorrhea.
## Adult Dosing
* **Mefenamic Acid Component:** Typically 250 mg to 500 mg every 8 hours as needed for pain. Maximum daily dose is 1500 mg.
* **Dicyclomine Hydrochloride Component:** Typically 20 mg every 8 hours as needed for spasms. Maximum daily dose is 40 mg.
* **Combination Product:** Dosing will depend on the specific formulation available. Follow manufacturer's recommendations or local protocol. If a 250mg mefenamic acid/20mg dicyclomine combination tablet is available, typical adult dosing is one tablet every 8 hours as needed.
## Pediatric Dosing
* Dosing for Meftal Spas in pediatric patients is not well-established. Mefenamic acid pediatric dosing is generally 5-7 mg/kg/dose every 8 hours. Dicyclomine is also not commonly used in pediatrics due to anticholinergic side effects. Use with extreme caution and only under strict medical supervision if prescribed.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Mefenamic acid is renally excreted. Severe renal impairment is a contraindication.
* **Hepatic Impairment:** Use with caution. Mefenamic acid is metabolized by the liver.
* **Elderly:** Increased risk of adverse effects, particularly gastrointestinal bleeding and renal toxicity. Use lower doses and monitor closely.
## Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or other NSAIDs.
* History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs.
* Inflammatory bowel disease.
* Glaucoma.
* Obstructive uropathy.
* Myasthenia gravis.
* Severe renal or hepatic impairment.
* Severe ulcerative colitis.
* Infants less than 6 months of age.
* Third trimester of pregnancy.
## Adverse Effects
* **Common (Mefenamic Acid):** Nausea, vomiting, diarrhea, abdominal pain, dyspepsia, rash.
* **Common (Dicyclomine):** Dry mouth, blurred vision, urinary retention, constipation, dizziness, drowsiness.
* **Serious:** Gastrointestinal bleeding, ulceration, perforation; cardiovascular thrombotic events; renal toxicity; hepatic toxicity; Stevens-Johnson syndrome; anaphylaxis.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Other NSAIDs and Aspirin:** Increased risk of GI toxicity.
* **Corticosteroids:** Increased risk of GI toxicity.
* **Diuretics and Antihypertensives:** NSAIDs can reduce their efficacy and increase the risk of renal toxicity.
* **Lithium:** NSAIDs can increase lithium levels.
* **Methotrexate:** NSAIDs can increase methotrexate toxicity.
* **Anticholinergics:** Additive anticholinergic effects with dicyclomine.
## Monitoring
* **Renal function:** Especially in patients with pre-existing renal disease, elderly patients, or those on concomitant nephrotoxic agents.
* **Hepatic function:** Periodically, especially in patients with liver disease.
* **Gastrointestinal symptoms:** Monitor for signs of bleeding (melena, hematemesis).
* **Blood pressure:** NSAIDs can cause or worsen hypertension.
* **Signs of anticholinergic toxicity** (e.g., confusion, urinary retention, blurred vision).
## Clinical Pearls
* Meftal Spas should be used at the lowest effective dose for the shortest duration necessary.
* Due to the anticholinergic component (dicyclomine), caution is advised in elderly patients and those with conditions exacerbated by anticholinergic agents (e.g., prostatic hypertrophy, bowel obstruction).
* Mefenamic acid should be taken with food or milk to minimize gastrointestinal upset.
* Discontinue use if severe GI symptoms, allergic reactions, or signs of renal/hepatic toxicity occur.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and current clinical guidelines. Dosing and safety information can vary. Always verify with the most current product information and patient-specific factors before prescribing or administering.
